Forecasting the Future of Multiple Myeloma
Ken Shain, MD, PhD, provides an overview of developments on the horizon in multiple myeloma.
Transcript:
I think it’s cool that there are other therapies that are hopefully going to be approved in the near future that are more—not to say traditional, but they’ll [provide] more options for our patients who are ineligible for CAR T or bispecific antibody therapy.
Secondly, most of the approved agents, from a cellular immunotherapy perspective, are based on harnessing the power of T cells, but there are other agents on their heels trying to harness the anti-tumor effects of other immune populations, like macrophages or natural killer cells. That's going to be a cool next step. [It’s going to be interesting to see] how we can use other arms of a patient’s immune system to affect the anti-myeloma activity of therapy.
Transcript edited for clarity.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
